Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINHALATIONGeneric

SEREVENT

SALMETEROL XINAFOATE

Standard Dose
EQ 0.021MG BASE/INH
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary

Approval overview SEREVENT is listed in Drugs@FDA under application 020236 (NDA).

Review priority: PRIORITY Marketing status: Discontinued Active ingredient SALMETEROL XINAFOATE Form and strength AEROSOL, METERED;INHALATION - EQ 0.021MG BASE/INH Sponsor GLAXOSMITHKLINE Submission history Latest submission status date: 2004-09-28 00:00:00.

Structured Monograph

Clinical summary

Approval overview SEREVENT is listed in Drugs@FDA under application 020236 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient SALMETEROL XINAFOATE Form and strength AEROSOL, METERED;INHALATION - EQ 0.021MG BASE/INH Sponsor GLAXOSMITHKLINE Submission history Latest submission status date: 2004-09-28 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.